Isatuximab-irfc (Sarclisa) - CPB - 0969 — CPB 0969 | AETNA Coverage Update

Aetna modified CPB 0969 for isatuximab-irfc (Sarclisa), effective March 3, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its isatuximab-irfc Sarclisa coverage policy under CPB 0969 in Aetna's commercial plan system. This policy governs when J9227 (injection, isatuximab-irfc, 10 mg) is medically necessary — and the revised criteria now spell out five distinct multiple myeloma treatment settings eligible for approval. If your oncology practice or infusion center bills J9227 alongside CPT 96413 or 96415 for IV chemotherapy administration, this policy update directly affects your prior authorization workflow.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Isatuximab-irfc (Sarclisa) — CPB 0969
Policy Code	CPB 0969
Change Type	Modified
Effective Date	March 3, 2026
Impact Level	High
Specialties Affected	Hematology/Oncology, Infusion Centers, Hospital Outpatient
Key Action	Audit your prior auth submissions for J9227 against all five approved myeloma regimen criteria before billing

---

Aetna Isatuximab-irfc (Sarclisa) Coverage Criteria and Medical Necessity Requirements 2026

The Aetna isatuximab-irfc coverage policy covers Sarclisa in two primary clinical categories: multiple myeloma and a set of rarer plasma cell disorders. Precertification is required for all Aetna participating providers and members in applicable plan designs — no exceptions.

To get prior authorization, call (866) 752-7021 or fax your Statement of Medical Necessity to (888) 267-3277.

Multiple Myeloma — Five Approved Regimens

Aetna considers J9227 medically necessary for multiple myeloma in any of these five settings:

1. Isatuximab + pomalidomide + dexamethasone (relapsed/refractory)
The member must have received at least two prior therapies for multiple myeloma, including lenalidomide and a proteasome inhibitor, if lenalidomide- or bortezomib-refractory.

2. Isatuximab + carfilzomib (J9047) + dexamethasone (relapsed/refractory)
The member must have received at least one prior line of therapy, if lenalidomide- or bortezomib-refractory.

3. Isatuximab + bortezomib (J9041) + lenalidomide + dexamethasone (primary therapy)
No prior therapy requirement — this is a front-line regimen setting.

4. Isatuximab + carfilzomib (J9047) + lenalidomide + dexamethasone (primary therapy)
The source policy text uses the phrase "transparent candidates" for this criterion. This appears to be a transcription error in the source document — the intended term is most likely "transplant candidates." Confirm eligibility language with Aetna directly before submitting a prior authorization under this pathway.

5. Isatuximab + lenalidomide + dexamethasone (primary therapy)
Approved for members who are deferred from transplant or ineligible for transplant.

The prior-line-of-therapy requirements in regimens one and two are the most common denial trigger. Document refractory status and prior treatment history explicitly in your prior authorization submission. A vague clinical summary will not hold up.

POEMS, MIDD, and MGRS — Covered Without Regimen-Specific Criteria

Aetna also considers isatuximab-irfc medically necessary for three rarer plasma cell-related conditions:

#	Covered Indication Copy
1	POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes)
2	MIDD (plasma cell-related monoclonal immunoglobulin deposition disease)
3	MGRS (plasma cell-related monoclonal gammopathy of renal significance)

Coverage for these conditions does not carry the same regimen-specific or prior-therapy criteria as the myeloma pathways. That said, precertification still applies. Don't skip the prior auth step because the criteria look simpler.

Continuation of Therapy

Aetna approves reauthorization when the member shows no evidence of unacceptable toxicity or disease progression on the current regimen. Your reauthorization submission needs to document treatment response. As a billing team best practice — not a verbatim policy requirement — that means pulling together lab values, imaging, and clinical notes before your reauth window opens. The policy specifies the standard; your documentation process should support it. Submitting a reauth without response documentation is a fast path to a claim denial.

---

Aetna Isatuximab-irfc Exclusions and Non-Covered Indications

Aetna considers all other indications for isatuximab-irfc experimental, investigational, or unproven. That language is a hard stop — not a gray area.

If your oncologist is using Sarclisa for an indication outside the five myeloma regimens or the three plasma cell disorders listed above, expect denial. This includes any off-label use not supported by the criteria in CPB 0969. The policy doesn't list specific off-label uses as examples; it simply draws a line at "all other indications."

If you're treating a patient with an unusual presentation that doesn't fit cleanly into one of the five myeloma regimens, talk to your compliance officer before submitting. A denied claim for an experimental indication is harder to appeal than one that was built wrong on submission.

---

Coverage Indications at a Glance

---

Aetna Isatuximab-irfc Billing Guidelines and Action Items 2026

The real issue with this coverage policy is how tightly the approval criteria tie to clinical documentation. You can submit the right codes and still get a claim denial if the medical record doesn't explicitly mirror the criteria language. Here's what to do now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Isatuximab-irfc Under CPB 0969

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9227	HCPCS	Injection, isatuximab-irfc, 10 mg

Supporting Combination Agent Codes

These codes appear in the policy for the combination regimens. Bill these alongside J9227 only when the specific agent is part of the PA-approved regimen for your patient.

Note on bortezomib codes: J9046, J9048, J9049, and J9051 are manufacturer-specific bortezomib codes that appear in the CPB 0969 policy code list. Use these only when bortezomib is the dispensed product and only the code that matches your specific product. Do not use these as interchangeable defaults for J9041.

Codes Listed in CPB 0969 That Are NOT Isatuximab Combination Agents

The following codes appear in the CPB 0969 policy code list but have no clinical relationship to isatuximab-irfc combination regimens. Do NOT bill these alongside J9227 as companion agents.

Code	Type	Description Copy
J9022	HCPCS	Injection, atezolizumab, 10 mg
J9119	HCPCS	Injection, cemiplimab-rwlc, 1 mg

Related CPT Administration Codes

Code	Type	Description Copy
96413	CPT	Chemotherapy administration, intravenous infusion technique, up to one hour
96415	CPT	Chemotherapy administration, intravenous infusion technique, each additional hour

Key ICD-10-CM Diagnosis Codes

The policy lists 698 ICD-10-CM codes. The primary myeloma and plasma cell disorder codes your billing team will use most are listed below. Confirm the full code set in the policy source at CPB 0969 on PayerPolicy.

The full ICD-10 code set includes 698 codes across multiple malignancy categories. Pull the complete list from the policy source before building your charge capture mapping. The breadth of that code list is unusual for a single drug policy — if your compliance officer hasn't reviewed the full ICD-10 scope of CPB 0969, that's worth a conversation before you see a claim denial for an unexpected code exclusion.

---